Twitter Facebook LinkedIn YouTube

THC BioMed Intl Ltd (CSE: THC) has provided a corporate update to its shareholders

Video Platform Video Management Video Solutions Video Player

On August 20, 2015, Health Canada inspectors conducted a second pre-licensing inspection of the company’s facility in Kelowna, British Columbia. As there were no further deficiencies indicated, the company remains optimistic that its application under the Marihuana for Medical Purposes Regulations will be approved and that it will be granted a license, although there is no assurance that this will happen.

Additional Information:

Company: THC BioMed Intl Ltd
Website: http://thcbiomed.com/
Stock Symbol: CSE: THC
Date Published: Sep 1, 2015
Transcript: Available

Video Transcript:

I’m Samantha Deutscher for Investmentpitch Media

THC BioMed Intl Ltd (CSE:THC) has provided a corporate update to its shareholders.

On August 20, 2015, Health Canada inspectors conducted a second pre-licensing inspection of the company’s facility in Kelowna, British Columbia.

As there were no further deficiencies indicated, the company remains optimistic that its application
under the Marihuana for Medical Purposes Regulations will be approved and that it will be granted a license, although there is no assurance that this will happen.

THC’s vision is to be on the leading edge of scientific research and development of products and services related to the medical cannabis industry.

As the industry develops, it will become more important to focus on scientific research and development of products and services related to medical cannabis.

The company plans to develop other products and services for MMPR Licensed producers, focusing on medical cannabis research & development, plant innovation and life sciences.

To date, there are 26 licensed marijuana producers in Canada, with 6 in British Columbia.

The company recently formed an Advisory Board, which consists of Don Shaxon who brings 20
years’ experience in the capital markets including a successful position as Corporate development Manager with Cannabis Science Inc. along with Mr. J. D. Springett, who brings 7 years’ experience in the newly emerging Medical Cannabis industry, beginning with Cannabis Science in 2008.

The shares are trading at $0.09 and with 76 million shares outstanding, the company is capitalized at $6.8 million.

For more information, please visit the company’s website www.thcbiomed.com or contact John Miller, President & CEO, at 1-844-842-6337 or email info@thcbiomed.com.

I’m Samantha Deutscher for Investmentpitch Media